A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
THURSDAY, 14 JUNE 2018
Conclusions: SSc-patients have markedly reduced muscle endurance and muscle function compared with reference values and patients with moderate-endstage lung disease have reduced lower extremity muscle function compared to patients with no-mild lung disease. SSc-patients have slightly less AROM than controls and dcSSc-patients are more restricted than lcSSc. This study highlights the importance of identifying patients with an enhanced risk of developing severe muscle impairments. We suggest thatdoi:10.1136/annrheumdis-2018-eular.2107 fatcat:mnplzskoonhf7c4pfjtdhn2rom